Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT – Get Free Report) saw a large decrease in short interest during the month of October. As of October 30th, there was short interest totaling 6,660 shares, a decrease of 46.0% from the October 15th total of 12,328 shares. Based on an average daily volume of 28,516 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the company’s stock are sold short.
Regentis Biomaterials Stock Down 1.6%
Shares of RGNT stock traded down $0.02 on Monday, hitting $1.21. The company’s stock had a trading volume of 11,776 shares, compared to its average volume of 1,581,577. Regentis Biomaterials has a fifty-two week low of $1.16 and a fifty-two week high of $15.50. The firm’s fifty day moving average price is $1.62 and its 200-day moving average price is $2.67.
Regentis Biomaterials (NYSEAMERICAN:RGNT – Get Free Report) last announced its quarterly earnings results on Friday, September 11th. The company reported ($0.22) earnings per share for the quarter.
Regentis Biomaterials Company Profile
Regentis Biomaterials is a medical technology company developing biomaterials for the repair of damaged cartilage. Its lead product, GelrinC, is an implant designed to treat focal cartilage defects in the knee. The cell-free hydrogel is placed in the defect and is intended to support the formation of repair tissue as the material gradually degrades. The company’s work focuses on providing an off-the-shelf alternative to cartilage-repair procedures that require harvesting a patient’s cells or tissue.
See Also
- Five stocks we like better than Regentis Biomaterials
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Regentis Biomaterials Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regentis Biomaterials and related companies with MarketBeat.com's FREE daily email newsletter.
